Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

MEN with the Angelina Jolie cancer genes should get routine prostate screening on the NHS from the age of 40, says the ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

Men with BRCA1 and BRCA2 gene mutations should be given annual prostate cancer screening checks, leading scientists have said ...

MEN with aggressive prostate cancer could benefit from a new drug combination that slows cancer growth, scientists say. Adding a drug already used against ovarian and fallopian tube cancers to ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

BRCA gene mutations are linked to a higher chance of developing prostate cancer at a younger age and in a more aggressive ...

With the backing of Rishi Sunak, Prostate Cancer UK published a report to the national screening committee back in 2022 in ...

An international study reports that the combination of two drugs could significantly retard the development of a dangerous ...

A new study shows that adding niraparib to standard prostate cancer treatment slows disease progression by up to 50% in men with BRCA mutations — a major breakthrough in precision medicine.

Adding PARP inhibitor niraparib to standard prostate cancer treatment delays disease progression in men with certain DNA ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a ...